ReNeuron delays Ph I neural stem cell trials
ReNeuron has delayed a Phase I study of its stem cell transplantationtechnology, in development as a treatment for diseases such as Alzheimer's and Parkinson's, due to stability problems. The company said that its stem cell lines had not shown sufficient stability after the multiple doublings required to create commercial quantities, and it has now implemented a program looking at alternative lines.
The trials were expected to begin at the end of this year, but ReNeuron expects a delay of around six months before they will now begin. News of the delay led to a 7% fall in ReNeuron's share price on the day (June 21) to L1.17 ($1.65). However, ReNeuron chief executive Martin Edwards stressed that, since no other company has started clinical trials of stem cells in neurological applications, the firm remains at the forefront of commercializing the technology.
Drug discovery alliance with VistaGen
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze